Published in Diabetes Care on March 18, 2010
Metformin Pharmacology in Human Cancers: A Proof of Principle Study | NCT03477162
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle (2010) 3.15
Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care (2012) 3.11
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) (2010) 2.60
Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res (2012) 2.17
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist (2012) 1.79
Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care (2014) 1.68
Potential applications for biguanides in oncology. J Clin Invest (2013) 1.63
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care (2011) 1.52
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res (2013) 1.49
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer (2011) 1.48
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther (2011) 1.43
Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis (2012) 1.41
Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist (2013) 1.41
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) (2014) 1.38
Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr (2013) 1.31
Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A (2015) 1.27
Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev (2012) 1.23
Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol (2011) 1.20
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol (2013) 1.20
Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res (Phila) (2012) 1.10
Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem (2011) 1.10
The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer (2012) 1.08
Gerosuppressant metformin: less is more. Aging (Albany NY) (2011) 1.08
The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. Cancer Causes Control (2012) 1.05
Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf (2013) 1.05
AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Res (2014) 1.04
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat (2011) 1.01
Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China. BMC Public Health (2012) 1.00
Hyperglycemia as a risk factor for cancer progression. Diabetes Metab J (2014) 0.99
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Oncotarget (2014) 0.99
Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget (2014) 0.98
Metabolism and breast cancer risk: frontiers in research and practice. J Acad Nutr Diet (2012) 0.96
AMP-Activated Protein Kinase α 2 Isoform Suppression in Primary Breast Cancer Alters AMPK Growth Control and Apoptotic Signaling. Genes Cancer (2013) 0.94
Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. Oncotarget (2014) 0.93
Thiazolodinediones and cancer: duplicate publication bias? Oncologist (2013) 0.91
Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling. Pancreas (2015) 0.91
Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer (2014) 0.89
Comment on: Suissa and Azoulay. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665-2673. Diabetes Care (2013) 0.88
Chronic exposure to nicotine enhances insulin sensitivity through α7 nicotinic acetylcholine receptor-STAT3 pathway. PLoS One (2012) 0.88
Changing the energy of an immune response. Am J Clin Exp Immunol (2013) 0.88
The maternal womb: a novel target for cancer prevention in the era of the obesity pandemic? Eur J Cancer Prev (2011) 0.88
Metformin effects revisited. Diabetes Res Clin Pract (2011) 0.88
Metabolic syndrome and breast cancer: is there a link? Breast Care (Basel) (2014) 0.88
Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget (2015) 0.87
Recent advances in the use of metformin: can treating diabetes prevent breast cancer? Biomed Res Int (2015) 0.87
Low and high linear energy transfer radiation sensitization of HCC cells by metformin. J Radiat Res (2013) 0.86
Relationship between diabetes and risk of second primary contralateral breast cancer. Breast Cancer Res Treat (2010) 0.86
Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer. Int J Mol Med (2015) 0.86
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. PLoS One (2013) 0.85
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res (2015) 0.85
Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One (2012) 0.85
Association between Metformin Therapy and Breast Cancer Incidence and Mortality: Evidence from a Meta-Analysis. J Breast Cancer (2015) 0.85
The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med (2014) 0.84
Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress. Oxid Med Cell Longev (2015) 0.84
lncRNA NBR2 modulates cancer cell sensitivity to phenformin through GLUT1. Cell Cycle (2016) 0.84
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol (2016) 0.83
Chemo/Dietary prevention of cancer: perspectives in China. J Biomed Res (2014) 0.83
Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk. ISRN Endocrinol (2013) 0.83
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. Curr Breast Cancer Rep (2014) 0.83
AMPK as a potential anticancer target - friend or foe? Curr Pharm Des (2014) 0.82
Cardiometabolic factors and breast cancer risk in U.S. black women. Breast Cancer Res Treat (2012) 0.82
Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer. Rambam Maimonides Med J (2012) 0.82
Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes. BMC Cancer (2015) 0.82
Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. Cancer Discov (2016) 0.82
Diabetes and risk of subsequent gastric cancer: a population-based cohort study in Taiwan. Gastric Cancer (2012) 0.82
Effects of sulfonylureas on tumor growth: a review of the literature. Oncologist (2013) 0.81
Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway. Exp Ther Med (2015) 0.81
Diabetes medications and cancer risk: review of the literature. Am Health Drug Benefits (2012) 0.81
Metformin and cancer in type 2 diabetes. Diabetes Metab J (2013) 0.81
Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. PLoS One (2016) 0.81
Evaluation of Diabetic Patients with Breast Cancer Treated with Metformin during Adjuvant Radiotherapy. Int J Breast Cancer (2013) 0.80
Prolonged Nightly Fasting and Breast Cancer Prognosis. JAMA Oncol (2016) 0.80
Metformin and breast and gynecological cancer risk among women with diabetes. BMJ Open Diabetes Res Care (2015) 0.79
Metabolic Syndrome and Breast Cancer Risk: Is There a Role for Metformin? Curr Breast Cancer Rep (2011) 0.79
Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study. PLoS One (2015) 0.79
Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative. Int J Cancer (2015) 0.79
Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia (2017) 0.78
Absence of caveolin-1 expression in carcinoma-associated fibroblasts of invasive micropapillary carcinoma of the breast predicts poor patient outcome. Virchows Arch (2014) 0.78
AMPK activation--protean potential for boosting healthspan. Age (Dordr) (2013) 0.78
Metformin and cancer. Rev Diabet Stud (2014) 0.78
Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol Res (2016) 0.78
Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling. J Cancer Res Clin Oncol (2015) 0.77
Effects of metformin on retinoblastoma growth in vitro and in vivo. Int J Oncol (2014) 0.77
Anti-Breast Cancer Potential of Quercetin via the Akt/AMPK/Mammalian Target of Rapamycin (mTOR) Signaling Cascade. PLoS One (2016) 0.77
Metabolic requirements for cancer cell proliferation. Cancer Metab (2016) 0.77
Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction. Cancers (Basel) (2012) 0.76
Cancer: Long-term use of metformin could protect against breast cancer. Nat Rev Endocrinol (2010) 0.76
No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study. BMC Cancer (2015) 0.76
Response to Bodmer et al. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes care 2012;35:2665-2673. Diabetes Care (2013) 0.76
Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin. Int J Mol Med (2013) 0.76
Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1. Cancers (Basel) (2015) 0.75
Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. Epidemiology (2017) 0.75
Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells. BMC Cancer (2017) 0.75
In reply. Oncologist (2013) 0.75
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Validity of the general practice research database. Pharmacotherapy (2003) 6.78
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol (2002) 4.55
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol (2007) 3.39
Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr (2007) 3.27
Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol (2005) 3.06
Use of thiazolidinediones and fracture risk. Arch Intern Med (2008) 2.99
Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care (2009) 2.90
Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev (2009) 2.66
The general practice research database: role in pharmacovigilance. Drug Saf (2004) 2.38
Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care (2008) 2.33
The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem (2008) 2.20
The incidence of breast cancer in the General Practice Research Database compared with national cancer registration data. Br J Cancer (2000) 2.17
The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat (2007) 1.98
Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat (1998) 1.77
Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol (2008) 1.47
Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat (2006) 1.21
Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr (2007) 1.15
Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study. J Am Acad Dermatol (2008) 0.97
Antidepressants and the risk of suicidal behaviors. JAMA (2004) 7.08
Validity of the general practice research database. Pharmacotherapy (2003) 6.78
Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology (2004) 3.21
Use of thiazolidinediones and fracture risk. Arch Intern Med (2008) 2.99
Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. J Pain (2010) 2.90
Cardiovascular flow measurement with phase-contrast MR imaging: basic facts and implementation. Radiographics (2002) 2.89
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J (2006) 2.87
Drug-related problems in hospitals: a review of the recent literature. Drug Saf (2007) 2.80
Development and evaluation of a quality-controlled ribosomal sequence database for 16S ribosomal DNA-based identification of Staphylococcus species. J Clin Microbiol (2004) 2.59
Use of antihypertensives and the risk of Parkinson disease. Neurology (2008) 2.51
Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care (2008) 2.33
Statin use and risk of gallstone disease followed by cholecystectomy. JAMA (2009) 2.31
Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab (2014) 2.18
Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol (2004) 2.11
Hepatitis B vaccination and multiple sclerosis: the jury is still out. Pharmacoepidemiol Drug Saf (2006) 2.06
Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab (2002) 1.94
Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. Crit Care Med (2005) 1.77
The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem (2008) 1.66
Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol (2002) 1.65
Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol (2009) 1.62
Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy (2007) 1.61
Use of beta-blockers and risk of fractures. JAMA (2004) 1.58
Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis (2003) 1.55
Cigarette smoking and the progression of multiple sclerosis. Brain (2005) 1.52
Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer (2005) 1.50
Acute mycophenolate overdose: case series and systematic literature analysis. Expert Opin Drug Saf (2014) 1.48
Antibiotic use and risk of multiple sclerosis. Am J Epidemiol (2006) 1.45
Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev (2011) 1.44
Diabetes mellitus and the risk of cholecystectomy. Dig Liver Dis (2011) 1.44
Incidence of the pneumoconioses in the United Kingdom general population between 1997 and 2008. Respiration (2012) 1.41
Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol (2010) 1.41
Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol (2011) 1.41
Association of infant pneumococcal vaccination with pneumococcal pneumonia among mothers: a nested case-control study using the GPRD. Vaccine (2013) 1.40
Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf (2007) 1.39
Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol (2011) 1.38
Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol (2002) 1.30
Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol (2005) 1.27
Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol (2012) 1.27
Dose adjustment in patients with liver disease. Drug Saf (2005) 1.26
Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf (2004) 1.25
COPD and the risk of depression. Chest (2009) 1.23
Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost (2005) 1.23
Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J Am Geriatr Soc (2012) 1.22
Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases. Clin Chem (2008) 1.19
Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med (2008) 1.18
Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol (2005) 1.17
Metformin does not alter the risk of lung cancer: a case-control analysis. Lung Cancer (2012) 1.17
Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology (2005) 1.15
Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol (2007) 1.14
Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One (2012) 1.13
Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. Acta Orthop (2012) 1.12
Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol (2009) 1.11
The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med (2010) 1.10
Systematic review of medication safety assessment methods. Am J Health Syst Pharm (2011) 1.08
Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol (2011) 1.07
Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab (2007) 1.07
Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother (2004) 1.06
Surgical Timing and the Menstrual Cycle Affect Wound Healing in Young Breast Reduction Patients. Plast Reconstr Surg (2016) 1.06
The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf (2004) 1.05
The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf (2006) 1.04
Evaluation of frequently used drug interaction screening programs. Pharm World Sci (2008) 1.03
Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medical and geriatric wards. Drugs Aging (2006) 1.03
Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med (2010) 1.03
Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD). Ann Hematol (2014) 1.02
Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf (2008) 1.02
Diabetes in patients with idiopathic Parkinson's disease. Diabetes Care (2008) 1.01
Characterization of the membrane-destabilizing properties of different pH-sensitive methacrylic acid copolymers. Biochim Biophys Acta (2003) 1.01
Appropriateness of serum level determinations of antiepileptic drugs. Swiss Med Wkly (2003) 1.01
Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med (2004) 1.00
Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging (2007) 1.00
Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol (2008) 1.00